Conversion Therapy of RAS/BRAF Wild-Type Right-Sided Colon Cancer Patients With Initially Unresectable Liver Metastases
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Interventions: Group 1:FOLFOX+Cetuximab;Group 2:FOLFOX + bevacizumab Primary outcome(s): conversion-to-resection rate Study Design: Parallel
创建时间：
2020-10-15
